{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:36:17Z","timestamp":1789814177143,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[1999,2,12]],"date-time":"1999-02-12T00:00:00Z","timestamp":918777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1038\/sj.bjc.6690184","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T14:03:06Z","timestamp":1032271386000},"page":"1158-1161","source":"Crossref","is-referenced-by-count":43,"title":["Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer"],"prefix":"10.1038","volume":"79","author":[{"given":"J M M","family":"Terwogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A M","family":"Mandjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Sindermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W W","family":"ten Bokkel Huinink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,2,12]]},"reference":[{"key":"BF6690184_CR1","first-page":"125","volume":"32","author":"K Ando","year":"1972","unstructured":"Ando, K., Kodama, K., Kato, A., Tamura, G. & Arima, K. (1972). Antitumor activity of glycerylethers. Cancer Res, 32: 125\u2013129.","journal-title":"Cancer Res"},{"key":"BF6690184_CR2","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/0959-8049(95)00350-9","volume":"31A","author":"D Berkovic","year":"1995","unstructured":"Berkovic, D., Grunwald, U., Menzel, W., Unger, C., Hiddeman, W. & Fleer, E. A. (1995). Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer, 31A: 2080\u20132085.","journal-title":"Eur J Cancer"},{"key":"BF6690184_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(05)61570-X","volume":"349","author":"S Clive","year":"1997","unstructured":"Clive, S. & Leonard, R. C. F. (1997). Miltefosine in recurrent cutaneous breast cancer. Lancet, 349: 621\u2013622.","journal-title":"Lancet"},{"key":"BF6690184_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/1523-1747.ep12373109","volume":"102","author":"M Detmar","year":"1994","unstructured":"Detmar, M., Geilen, C. C., Wieder, T., Orfanos, C. E. & Reuter, W. (1994). Phospholipid analogue hexadecylphosphocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro. J Inv Derm, 102: 490\u2013494.","journal-title":"J Inv Derm"},{"key":"BF6690184_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0190-9622(93)70275-X","volume":"29","author":"R Dummer","year":"1993","unstructured":"Dummer, R., Krasovec, M., Roeger, J., Sindermann, H. & Burg, G. (1993). Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I\/II study. J Am Academy Derm 29: 963\u2013970.","journal-title":"J Am Academy Derm"},{"key":"BF6690184_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0305-7372(90)90053-I","volume":"17","author":"H Eibl","year":"1990","unstructured":"Eibl, H. & Unger, C. (1990). Hexadecylphosphocholine, a new and selective antitumor drug. Cancer Treatment Rev, 17: 233\u2013242.","journal-title":"Cancer Treatment Rev"},{"key":"BF6690184_CR7","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1007\/BF02579867","volume":"111","author":"H Eibl","year":"1986","unstructured":"Eibl, H., Unger, C., Fleer, E. A. M., Kim, D. J., Berger, M. R. & Nagel, G. A. (1986). Hexadecylphosphocholine, a new antineoplastic agent: cytotoxic properties in leukaemic cells. J Cancer Res Clin Oncol, 111: S24","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF6690184_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF00666004","volume":"32","author":"I Fichtner","year":"1994","unstructured":"Fichtner, I., Zeisig, R., Naundorf, H., Jungmann, S., Arndt, D., Asongwe, G., Double, J. A. & Bibby, M. C. (1994). Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Res Treatment, 32: 269\u2013279.","journal-title":"Breast Cancer Res Treatment"},{"key":"BF6690184_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF00686838","volume":"35","author":"M Goppelt-Struebe","year":"1995","unstructured":"Goppelt-Struebe, M. & Winter, I. (1995). Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity. Cancer Chemother Pharmacol, 35: 519\u2013526.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690184_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/0277-5379(88)90336-7","volume":"24","author":"P Hilgard","year":"1988","unstructured":"Hilgard, P., Stekar, J., Voegeli, R., Engel, J., Schumacher, W., Eibl, H., Unger, C. & Berger, M. R. (1988). Characterization of the anti-tumor activity of hexadecylphosphocholine. Eur J Cancer Clin Oncol, 24: 1457\u20131461.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6690184_CR11","first-page":"2310","volume":"30","author":"P Hilgard","year":"1989","unstructured":"Hilgard, P., Harleman, J. H., Voegeli, R., Maurer, H. R., Echarti, C. & Unger, C. (1989). The antineoplastic activity of hexadecylphosphocholines. Proc Am Ass Cancer Res, 30: 2310","journal-title":"Proc Am Ass Cancer Res"},{"key":"BF6690184_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/BF00685608","volume":"32","author":"P Hilgard","year":"1993","unstructured":"Hilgard, P., Klenner, T., Stekar, J. & Unger, C. (1993). Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharm, 32: 90\u201395.","journal-title":"Cancer Chemother Pharm"},{"key":"BF6690184_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0959-8049(05)80142-X","volume":"29A","author":"AST Planting","year":"1993","unstructured":"Planting, A. S. T., Stoter, G. & Verweij, J. (1993). Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer, 29A: 518\u2013519.","journal-title":"Eur J Cancer"},{"key":"BF6690184_CR14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/BF02536578","volume":"26","author":"C Unger","year":"1991","unstructured":"Unger, C. & Eibl, H. (1991). Hexadecylphosphocholine: preclinical and first clinical results of a new antitumor drug. Lipids, 26: 1412\u20131417.","journal-title":"Lipids"},{"key":"BF6690184_CR15","first-page":"25","volume":"20","author":"C Unger","year":"1984","unstructured":"Unger, C., Eibl, H., von Heyden, H. W. & Nagel, G. A. (1984). Reversible opening of the blood-brain-barrier for drugs transfer by short-chain alkyl glycerols. Proc Am Soc Clin Oncol, 20: 25","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690184_CR16","first-page":"S40","volume":"114","author":"C Unger","year":"1988","unstructured":"Unger, C., von Heyden, H. W., Breiser, A., Nagel, C. A. & Eibl, H. (1988). Etherlipids in the topical treatment of skin metastases. J Cancer Res Clin Oncol, 114: S40","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF6690184_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/02841868909111249","volume":"28","author":"C Unger","year":"1989","unstructured":"Unger, C., Damenz, W., Fleer, E. A. M., Kim, D. J., Breiser, A., Hilgard, P., Engel, J., Nagel, G. & Eibl, H. (1989). Hexadecylphosphocholine, a new ether lipid analogue. Acta Oncologica, 28: 213\u2013217.","journal-title":"Acta Oncologica"},{"key":"BF6690184_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0305-7372(90)90054-J","volume":"17","author":"C Unger","year":"1990","unstructured":"Unger, C., Peukert, M., Sindermann, H., Hilgard, P., Nagel, G. & Eibl, H. (1990). Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treatment Rev, 17: 243\u2013246.","journal-title":"Cancer Treatment Rev"},{"key":"BF6690184_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000420840","volume":"34","author":"C Unger","year":"1992","unstructured":"Unger, C., Sindermann, H., Peukert, M., Hilgard, P., Engel, J. & Eibl, H. (1992). Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Progr Exp Tumor Res, 34: 153\u2013159.","journal-title":"Progr Exp Tumor Res"},{"key":"BF6690184_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/BF01211805","volume":"118","author":"J Verweij","year":"1992","unstructured":"Verweij, J., Planting, A., van der Burg, M. & Stoter, G. (1992). A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol, 118: 606\u2013608.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF6690184_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0959-8049(93)90177-H","volume":"29A","author":"J Verweij","year":"1993","unstructured":"Verweij, J., Krzemieniecki, K., Kok, T., Poveda, A., van Pottelsberghe, C., van Glabbeke, M. & Mouridsen, H. (1993). Phase II study of miltefosine in advanced soft tissue sarcomas of the adult \u2013 an EORTC soft tissue and bone sarcoma group study. Eur J Cancer, 29A: 208\u2013209.","journal-title":"Eur J Cancer"},{"key":"BF6690184_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0959-8049(05)80369-7","volume":"29A","author":"J Verweij","year":"1993","unstructured":"Verweij, J., Gandia, D., Planting, A. S. T., Stoter, G. & Armand, J. P. (1993). Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer, 29A: 778\u2013779.","journal-title":"Eur J Cancer"},{"key":"BF6690184_CR23","unstructured":"WHO (1997). WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690184","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:51:04Z","timestamp":1684414264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2,12]]},"references-count":23,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["BF6690184"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690184","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2,12]]}}}